KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Depreciation & Amortization (CF) (2016 - 2025)

Pfizer (PFE) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 5.81% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 billion, a 6.0% decrease, with the full-year FY2025 number at $6.6 billion, down 6.0% from a year prior.
  • Depreciation & Amortization (CF) was $1.7 billion for Q4 2025 at Pfizer, up from $1.7 billion in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.9 billion in Q4 2021 to a low of $1.2 billion in Q3 2022.
  • A 5-year average of $1.8 billion and a median of $1.6 billion in 2025 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 33.87% in 2023; the steepest drop was 55.99% in 2023.
  • Pfizer's Depreciation & Amortization (CF) stood at $3.9 billion in 2021, then fell by 8.07% to $3.5 billion in 2022, then plummeted by 52.89% to $1.7 billion in 2023, then rose by 7.25% to $1.8 billion in 2024, then decreased by 5.81% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Depreciation & Amortization (CF) are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.6 billion (Q2 2025).